Russia to provide additional funding for full cycle vaccines production

The Russian government plans to provide additional funding for the establishment of a full production cycle of a number of vaccines within the country this year and to ensure their stable supplies for state needs, The Pharma Letter’s local correspondent reports.

In recent years the production of certain vaccines in Russia has already begun, however as part of plans of the Russian state and local drugmakers is creating conditions for a further increase of production.

For example, the production of Cegardex, an HPV vaccine, began in Russia in October 2025. It was launched on a full cycle basis at the industrial facilities of the biopharmaceutical company Nanolek. According to Nanolek’s chief executive Evgeny Barinov, the first batches of the vaccine will be supplied to the market in the second half of 2026, and by 2027, the company plans to completely cover the needs of the Russian healthcare sector in such vaccine.